Advanced Filters
noise

melanoma Clinical Trials

A listing of melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 470 clinical trials
R Reinhard Told, MD, PhD, Priv.-Doz.

Uveal Melanoma - Comparative Study

The progress of uveal melanoma is typically monitored with sonography by experienced onco-ophthalmologists. However, there is evidence that twodimensional measurements in color fundus photography match precisely with sonography measurements. This study aims to compare sonography and color fundus photography measurements in order to evaluate the feasibility of monitoring of uveal …

18 - 99 years of age All Phase N/A

Eye Plaque Brachytherapy for Ocular Melanoma

This prospective registry study will evaluate doses utilized in eye plaque brachytherapy for the treatment of ocular melanoma and their associated outcomes. The goal of this study is to evaluate if lower doses of radiation can maintain high local control rates while minimizing the toxicities related to radiation therapy.

18 years of age All Phase N/A
D Danielle Bednarz, RN, BSN

Evaluation of Hypoxia in Primary Melanoma

When controlling for tumor present in the Sentinel lymph node (SLN), intranodal hypoxia, as measured by Carbonic Anhydrase IX (CAIX IHC), is associated with worse PFS. This suggests that melanoma tumors may be utilizing deregulated metabolism as a means of propagating themselves to the next station of metastasis. This study …

18 years of age All Phase N/A
E Emanual Maverakis, MD

Characterization of the Melanoma-Specific Immune Response

The aim of this study is to study T-cells. Blood will be collected and the samples will be used to generate T cell clones. Two separate blood draws will be required at the maximum.

18 - 85 years of age All Phase N/A

Serial Tumour Biopsies and Blood Biomarkers in Melanoma

Recent advances in understanding how cancer develops and spreads have led to effective new treatments and improved outcomes for patients with melanoma. However, we know that these new treatments do not work for all patients: some do not respond to them and some initially respond but then develop resistance. The …

16 years of age All Phase N/A
A Aleuna Lee

Identification of Metabolic Phenotypes Associated With Melanoma Metastasis

The goal of this study is to observe metabolic features associated with human melanoma tumors.

18 years of age All Phase N/A
J Jumin Sunde, MD

In Vivo Real-time Detection of Circulating Melanoma Cells

The objective of this clinical trial is to determine whether a Photoacoustic flow cytometry (PAFC)-based prototype device can detect circulating tumor cells (CTCs) in the blood of melanoma patients in vivo, in real time, and do so at detection limits at least one order of magnitude below the detection limits …

18 - 80 years of age All Phase N/A

UK ENcorafenib and BInimetinib Real-world Study in Melanoma

This is a prospective longitudinal multi-centre observational study conducted in the United Kingdom, in patients with metastatic cutaneous BRAF V600 mutation-positive melanoma assigned to receive encorafenib and binimetinib. The aim of this study is to learn about how encorafenib and binimetinib perform, patients' experiences of using them, and how they …

18 years of age All Phase N/A
M Mohamed H Abdel-Rahman, MD, PhD

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1. Our study will ultimately facilitate the development of novel screening, prevention and treatment strategies for these individuals with …

years of age All Phase N/A
A Amy Rose, RN, BSN

Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

Melanoma in-transit metastases (ITMs) continue to represent a therapeutic dilemma, in that no standard method of treatment has been uniformly adopted. The complexity and heterogeneity of patient and disease characteristics, including the location and number of ITMs presents a barrier to a one size fits all treatment approach. Treatment of …

18 years of age All Phase N/A

Simplify language using AI